Brief: Paion Starts Study Of Remimazolam In Pediatric Procedural Sedation
16/09/2021 13:14
Sept 16 (Reuters) - PAION AG PA8G.DE :
* ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM
(BYFAVO(R))
IN PEDIATRIC PROCEDURAL SEDATION
Source text for Eikon: ID:nEQ2TsWfa
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((Gdansk.Newsroom@thomsonreuters.com;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022